Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 24-Feb-2022 16:08:08. This version was issued on 24-Feb-2022 16:08:08

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive
  • DHSC Supply Disruption - Medicines

Action category: Action

Title: Remdesivir for patients hospitalised due to COVID-19 (adults and adolescents 12 years and older)

Broadcast content:

***05/05/2022 - An updated Clinical guide has been attached following publication.***

The published policy has been updated to reflect the latest available information on the use of remdesivir in patients admitted to hospital due to COVID-19.  A graphical clinical guide (attached below), summarising the main COVID treatment options available to this patient cohort, is also provided to support clinical decision making.  The updated policy provides links to the two other published clinical access policies supporting the use of remdesivir in
patients with hospital-onset COVID infection, and non-hospitalised patients at highest risk from COVID infection, respectively. 

Additional information: This alert does not need to be cascaded to Primary Care

Alert reference: CEM/CMO/2022/006


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency